NSSG Chemotherapy Protocol
patients should be offered fertility advice by referring to the Oxford Fertility Unit. 12. Hydration - in patients with bulky disease pre-hydrate with sodium chloride 0.9% 1 litre over 4-6 hours. For patients at high risk of tumour lysis, refer to the tumour lysis protocol.by 13.
Download NSSG Chemotherapy Protocol
Information
Domain:
Source:
Link to this page:
Documents from same domain
CYCLOPHOSPHAMIDE / BORTEZOMIB/ …
nssg.oxford-haematology.org.ukMyeloma group This is a controlled document and therefore must not be changed of MM.11 CyBorDex- Amyloidosis Authorised by …
Cyclophosphamide priming prior to PBSC harvest
nssg.oxford-haematology.org.ukDepartment of Clinical Haematology Oxford BMT Programme B.2.20b Page 1 of 3 May 2017 V.5.4 Cyclo prime for Myeloma PSBC Harvest Authorised by: Dr Karthik Ramasamy
ATTENUATED CYCLOPHOSPHAMIDE, THALIDOMIDE & …
nssg.oxford-haematology.org.ukMyeloma group This is a controlled document and therefore must not be changed MM.9 CTD - attenuated Authorised by Myeloma lead Dr. Karthik Ramasamy July 2017
Guidelines for the Management of Hypomagnesaemia …
nssg.oxford-haematology.org.ukDepartment of Clinical Haematology H.95 Page 2 of 5 November 2015 V.1.0. Guidelines for the management of hypomagnesaemia in Adult Clinical Haematology
Oxford Myeloma Group
nssg.oxford-haematology.org.ukMM.50 VTDPACE/DTPACE Authorised by Myeloma lead Dr. Karthik Ramasamy June 2022 V. 2.0 of 10 Days Drug Dose Route Comments 1 to 4 Dexamethasone 40 mg daily Oral Continuous daily/ If PBSC harvest planned only for days 1 to 4 Thalidomide (See note below) Start 50 mg and increase up to 100 mg as tolerated Oral Nocte 1 to 4
MATRix (High dose METHOTREXATE, high dose CYTARABINE ...
nssg.oxford-haematology.org.uk- Reduce thiotepa dose to 75% - Reduce methotrexate to 2g/m2 Haematological toxicity In case if inadequate bone marrow recovery (i.e. neutrophils < 1.5x109/L and platelets < 90x109/L on the intended day of re-treatment, delay cycle until counts satisfactory. Doses of the chemotherapy
ISATUXIMAB WITH POMALIDOMIDE AND …
nssg.oxford-haematology.org.ukvolume Initial rate Absence of infusion reaction Rate increment Maximum rate First infusion 250 mL 25 mL/ hour For 60 minutes 25 mL/hour every 30 minutes 150 mL/ hour Second infusion 250 mL 50 mL/ hour For 30 minutes 50 mL/ hour for 30 minutes then increase by 100 mL/ hr every 30 minutes 200 mL/ hour Subsequent infusions
ATRA + ARSENIC TRIOXIDE
nssg.oxford-haematology.org.ukArsenic Trioxide infusion duration may be extended up to 4 hours if vasomotor reactions, e.g. flushing, tachycardia and dizziness, are observed. If patients suffer severe symptoms or hypotension then the infusion should be stopped until recovery and then recommenced at a
High dose METHOTREXATE (high grade NHL CNS …
nssg.oxford-haematology.org.ukadults receiving high-dose methotrexate chemotherapy (doses >1g/m2) - Who develop significant deterioration in renal function (>1.5x ULN and rising, or the presence of oliguria) OR - Have toxic plasma methotrexate level AND - Have been treated with all standard rescue and supportive measures AND
ESHAP and R-ESHAP
nssg.oxford-haematology.org.uk2. Record stage of disease - contrast enhanced CT scan (neck, chest, abdomen and pelvis), ... In order to eliminate the risk of transmitting infective ... After 1-2 cycles with CT or PET-CT. Lymphoma group This is a controlled document and therefore must …
Related documents
HIV Pre-Exposure Prophylaxis (PrEP): A brief guide for ...
paetc.org4. Patients have to re-apply (i.e. resubmit proof of eligibility) every 3-6 months. Note for patients without social security numbers: a proof of residence can be submitted instead, such as a phone or utility bill in their name and address, or a notarized letter with their name and address.
Ministry of Health & Family Welfare Directorate General of ...
www.mohfw.gov.in1.3. Wherever a COVID Care Center is designated for admitting both the confirmed and the suspected cases, these facilities must have separate areas for suspected and confirmed cases with preferably separate entry and exit. Suspect and confirmed cases must not be allowed to mix under any circumstances. 1.4.
NATIONAL CLINICAL MANAGEMENT PROTOCOL COVID-19
www.mohfw.gov.inConfirmed case Source: 1 As per WHO surveillance guidelines 5. Clinical Features COVID-19 patients reporting to various Covid treatment facilities have reported the following signs and symptoms: • Fever, • cough, • general weakness/ fatigue, • headache, • myalgia, • sore throat, coryza, • dyspnoea,